Modulating insulin receptor signaling through targeting facl
CA 2462587 A1 · Owner: Exelixis, Inc. · Inventors: O'Brien, Carol L.; Kadyk, Lisa C.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Human FACL genes are identified as modulators of INR signaling and thus are therapeutic targets for disorders associated with defective INR signaling. Methods for identifying modulators of FACL comprising screeing for agents , that modulate the activity of FACL are provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 18, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 18, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 18, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.